Ophthalmic Drug Formulations

Clinical Ocular Pharmacology

Volumn , Issue , 2008, Pages 17-37

  Fiscella, Richard G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882473137     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-7576-5.50007-0     Document Type: Chapter

References (52)

1. Adams J, Wilcox MJ, Trousdale MD, et al. Morphologic and physiologic effects of artificial tear formulations on corneal epithelium derived cells. Cornea 1992, 11:234-241.
2. Ahmed I, Patton TF Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthal Vis Sci 1992, 33:581-595.
3. Ali Y, Lehmussaari K Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev 2006, (July 31).
4. Balazs EA, Denlinger JL The vitreous. The eye 1984, 533-589. Academic Press, New York. ed. 3. H. Davson (Ed.).
5. Ophthalmic drug facts 2007, J. B. Lippincott, St. Louis, MO. J.D. Bartlett, E.S. Bennett, R. Fiscella (Eds.).
6. Baudouin C, Pisella P, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Ophthalmology 1999, 106:556-563.
7. Bito LZ, DeRousseau CJ Transport functions of the blood-retinal barrier system of the micro environment of the retina. The blood-retinal barriers 1980, 133-163. Plenum Press, New York. J. Cunha-Vaz (Ed.).
8. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006, (July 31).
9. Burstein NL Corneal cytotoxicity of topically applied drugs, vehicles, and preservatives. Surv Ophthalmol 1980, 25:15-30.
10. Burstein NL Preservative alteration of corneal permeability in humans and rabbits. Invest Ophthalmol Vis Sci 1984, 25:1453-1457.
11. Burstein NL Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci 1980, 19:308-313.
12. Burstein NL The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc U K 1985, 104:402-409.
13. Burstein NL, Anderson JA Review: corneal penetration and ocular bioavailability of drugs. J Ocular Pharmacol 1985, 1:309-326.
14. Burstein NL, Bernacchi D, Leopold IH Gentamicin iontophoresis into vitreous humor. J Ocular Pharmacol 1985, 1:63-368.
15. Canon J, Fiscella R, Pattharachayakul S, et al. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci 2003, 44:2112-2117.
16. Chang DF, Garcia IH, Hinkeler JD, Minas T Phase II results of an intraocular steroid delivery system for cataract surgery. Ophthalmology 1999, 106:1172-1177.
17. Cunha-Vaz J The blood-ocular barriers. Surv Ophthalmol 1979, 23:279-296.
18. Desaint JM, Brignole F, Bringuier A, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999, 40:619-630.
19. Duvvuri S, Rittenhouse KD, Mitra AK Micodialysis assessment of drug delivery systems for vitreosretinal targets. Adv Drug Deliv Rev 2005, 57:2080-2091.
20. Fiscella R, Burstein NL Ophthalmic drug formulations. Clinical ocular pharmacology 2001, Butterworth Heinemann, Boston. ed. 4. J.D. Bartlett, S.D. Jaanus (Eds.).
21. Fiscella R, Lai WW, Buerk B, et al. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology 2004, 111:1191-1195.
22. Fiscella R, Nguyen T, Cwik MJ, et al. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999, 106:2286-2290.
23. Fisher RF, Hayes BP Thickness and volume constants and ultra-structural organization of basement membrane (lens capsule). J Physiol 1979, 293:229-245.
24. Fraunfelder FT, Fraunfelder FW Drug-induced ocular side effects 2001, Butterworth Heinemann, Boston. ed. 5.
25. Friedlaender M External disease and allergy. Current topics in ocular inflammation 1993, 29-34. Postgraduate Institute for Medicine, Littleton, CO. P.P. Ellis (Ed.).
26. Gaynes B, Fiscella R Topical non-steroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use: a safety review. Drug Saf 2002, 25:233-250.
27. Ghate D Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006, 3:275-287.
28. Gray RH, Franklin SJ, Reeves BC Visual recovery using small dilating drops. J Pharm Pharmacol 1992, 44:682-684.
29. Greaves JL, Wilson CG, Rozier A, et al. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res 1990, 9:415-420.
30. Green K, Livingston V, Bowman K Chlorhexidine effects on corneal epithelium and endothelium. Arch Ophthalmol 1980, 98:1273-1278.
31. Gunning FB, Greve EL, Bron AM, et al. Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study. Graefe's Arch Clin Exp Ophthalmol 1993, 231:384-388.
32. Hardberger R, Hanna C, Boyd CM Effects of drug vehicles on ocular contact time. Arch Ophthalmol 1975, 93:42-45.
33. Hosoya K, Lee VHL, Kim KJ Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm 2005, 60:227-240.
34. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005, 57:2010-2032.
35. Jadhav KR, Shaikh IM, Ambade KW, Kadam VJ Applications of microemulsion based drug delivery system. Curr Drug Deliv 2006, 3:267-273.
36. Kaila T, Salminen L, Huupponen R Systemic absorption of topically applied ocular timolol. J Ocular Pharmacol 1985, 1:79-83.
37. Koevary SB Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab 2003, 4:213-222.
38. Madhu C, Rix P, Nguyen T, et al. Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro. J Ocul Pharmacol Ther 1998, 14:389-399.
39. Marmor MF Sildenafil (Viagra) and ophthalmology. Arch Ophthalmol 1999, 117:518-519.
40. Maurice DM Injection of drugs into the vitreous body. Symposium on ocular therapy 1976, 59-71. John Wiley & Sons, New York. I.H. Leopold, R.P. Burns (Eds.).
41. Maurice DM, Mishima S Ocular pharmacokinetics. Pharmacology of the eye: handbook of experimental pharmacology 1984, 69:19-116. Springer-Verlag, Berlin. M.L. Sears (Ed.).
42. Moshfeghi AA, Peyman GA Micro and nanoparticulates. Adv Drug Deliv Rev 2005, 57:2047-2052.
43. Nelson JD, Helms H, Fiscella R, et al. A new look at dry eye disease and its treatment. Adv Ther 2000, 17(2):84-92.
44. Ranta VP, Urtti A Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev 2006, (Sep 15).
45. Rozier A, Mazuel C, Grove J, et al. Gelrite: a novel ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharmacol 1989, 57:163-168.
46. Sultana Y, Jain R, Aqil M, Ali A Review of ocular drug delivery. Curr Drug Deliv 2006, 3:207-217.
47. Szejtli L Medicinal applications of cyclodextrins. Med Res Rev 1994, 14:353-386.
48. Tan DT, Chee S, Lim L, Lim A Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 1999, 106:223-231.
49. Urtti A Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006, (July 31).
50. Urtti A, Salminen L Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 1993, 37:435-456.
51. Van Santvliet L, Ludwig A Determinants of eye drop size. Surv Ophthalmol 2004, 49:197-213.
52. Yasukawa T, Ogura Y, Kumura H, et al. Drug delivery from ocular implants. Expert Opin Drug Deliv 2006, 3:261-273.